RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6^th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25^th Annual Global Investment Conference on Wednesday, September 13^th in New York at 12:30 p.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Contact:
John Bluth
+1 919 859 7910
This email address is being protected from spambots. You need JavaScript enabled to view it.